Document Type
Article
Abstract
Introduction:
Exercise has demonstrated safety and efficacy in mitigating treatment-related symptoms across cancer populations; however, evidence in neuro-oncology remains limited, particularly during active chemoradiation.
Methods:
We report the case of a 63-year-old individual with newly diagnosed glioblastoma, experiencing symptoms of fatigue, balance issues, headaches, and memory loss, who initiated a 12-week supervised resistance training program during concurrent chemoradiation. Assessments at baseline and post-intervention included physical function and quality-of-life outcomes.
Results:
Adherence was 56% (20/36 sessions), and no adverse events occurred. The patient showed improvements in 6-minute walk distance and short physical performance battery score that exceeded established minimal clinically important differences. Quality-of-life findings were mixed, with certain domains benefiting from the exercise intervention and others worsening.
Discussion:
This case highlights the feasibility and safety of supervised resistance training during active glioblastoma chemoradiation. The observed improvements in physical function and select quality-of-life domains represent exploratory signals that compare favorably with the extant exercise oncology literature.
Digital Object Identifier (DOI)
Publication Info
Published in Frontiers in Oncology, Volume 16, 2026.
Rights
© 2026 Nakfoor and Fairman.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
APA Citation
Nakfoor, B., & Fairman, C. M. (2026). Supervised resistance training in an individual with glioblastoma undergoing chemoradiation: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1711875